Protocol Ledger

NCT05226871 · Phase II · ACTIVE NOT RECRUITING

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Interventional Phase II clinical trial protocol NCT05226871 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-07 Enrollment: 35 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05226871
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)35 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05226871
Protocol FieldVerified Registry Value
NCT IdentifierNCT05226871
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment35 participants (ACTUAL)
Registered Start Date2022-07-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI